Back to Search
Start Over
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2019 Jul; Vol. 81 (1), pp. 143-151. Date of Electronic Publication: 2019 Feb 27. - Publication Year :
- 2019
-
Abstract
- Background: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.<br />Objective: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.<br />Methods: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up.<br />Results: We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10 <superscript>-9</superscript> and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10 <superscript>-9</superscript> , respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm <superscript>3</superscript> ) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10 <superscript>-6</superscript> ). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs.<br />Limitations: No control group, missing data.<br />Conclusion: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.<br /> (Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal, Humanized
Cohort Studies
Conjunctivitis epidemiology
Dermatitis, Atopic diagnosis
Dose-Response Relationship, Drug
Drug Administration Schedule
Eosinophilia epidemiology
Female
France
Humans
Injections, Subcutaneous
Kaplan-Meier Estimate
Male
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Severity of Illness Index
Antibodies, Monoclonal therapeutic use
Conjunctivitis chemically induced
Dermatitis, Atopic drug therapy
Eosinophilia chemically induced
Patient Safety statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6787
- Volume :
- 81
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 30825533
- Full Text :
- https://doi.org/10.1016/j.jaad.2019.02.053